BPA for letairis

Ended Awarded Last action

Contract number
36E79718A0003
Awardee
Awarding agency
Task orders
6 $675,514 obligated

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Combined order value
$675,514 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 5% used
$13,734,190.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

Task orders

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00020 · Product add and deletion $0
Supplemental Agreement for work within scope P00021 · Updated ordering forms for yescarta and tecartus $0
Supplemental Agreement for work within scope P00019 · 2022 public law pricing updates $0
Exercise an Option P00018 · Exercise the 4TH and final option year on BPA 36E79718A0003. $0
Supplemental Agreement for work within scope P00017 · Update to voluntary temporary price reduction (TPR). $0
Supplemental Agreement for work within scope P00016 · Modification to delete NDC 61958-2902-01 from the BPA because remdesivir-veklury is now available via the VA's pharmaceutical prime vendor (PPV) program. $0
Other Administrative Action P00015 · Change in ordering instructions and forms for letairis. $0
Supplemental Agreement for work within scope P00014 · Temporary price reduction - letairis $0
Supplemental Agreement for work within scope P00013 · 2021 public law pricing updates $0
Supplemental Agreement for work within scope P00012 · NDC change (REMDESIVIR) $0
Supplemental Agreement for work within scope P00011 · Product add (REMDESIVIR) $0
Exercise an Option P00010 · Exercise the 3RD option year on the BPA. $0
Supplemental Agreement for work within scope P00009 · Product addition - yescarta $0
Supplemental Agreement for work within scope P00008 · 2020 public law pricing updates and TPR $0
Exercise an Option P00007 · Exercise the 2ND option year on BPA 36E79718A0003 $0
Supplemental Agreement for work within scope P00006 · Letairis TPR $0
Supplemental Agreement for work within scope P00005 · 2019 public law updates $0
Exercise an Option P00004 · Exercise option YR 1 $0
Other Administrative Action P00003 · Revised letairis ordering forms $0
Supplemental Agreement for work within scope P00002 · Temporary price reduction $0
Supplemental Agreement for work within scope P00001 · 2018 public law updates $0
Original award $0
Show all 22

Quick answers

Who was awarded contract 36E79718A0003?

36E79718A0003 was awarded to Gilead Sciences Inc. by National Acquisition Center (Headquarters) on November 1, 2017.

How much is contract 36E79718A0003 worth?

Orders under 36E79718A0003 have obligated $675,514. 36E79718A0003's own ceiling is $13,734,190.

How many orders have been placed under contract 36E79718A0003?

6 orders have been placed under 36E79718A0003, the latest on September 24, 2021.

Who can order from contract 36E79718A0003?

36E79718A0003 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79718A0003 under another contract?

Yes. 36E79718A0003 is a blanket purchase agreement under V797D70252, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79718A0003 competed?

The extent of competition for 36E79718A0003 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV